ANRO — Alto Neuroscience Income Statement
0.000.00%
Last trade - 00:00- $654.88m
- $497.38m
Annual income statement for Alto Neuroscience, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.21 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 12.3 | 29.2 | 37.8 | 68.6 | 67 |
| Operating Profit | -12.1 | -29.2 | -37.8 | -68.6 | -67 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -9.19 | -27.7 | -36.3 | -61.4 | -63.2 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -9.19 | -27.7 | -36.3 | -61.4 | -63.2 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -9.19 | -27.7 | -36.3 | -61.4 | -63.2 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -9.19 | -27.7 | -36.3 | -61.4 | -63.2 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.359 | -1.08 | -1.42 | -2.5 | -2.17 |
| Dividends per Share |